This is a working overview of tesamorelin, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-08. Anything still debated is marked as such rather than presented as settled.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
=== Possible expansion into other Latin American nations === In August of 2026, while visiting Panama, Hegseth proclaimed that the United States has made a military agreement with Colombia, Guatemala and Honduras to combat criminal drug organizations. Hegseth added that like the attacks on boats that the U.S. had been conducting in the East Pacific and the Caribbean, the attacks on drug traffickers on land would be the same. In addition, Hegseth stated that the U.S. would continue to pursue military cooperation with Ecuador. However, Guatemala later publicly repudiated Hegseth's claims.
is completely uniform, and by convention we direct it "into the page" along the negative z-axis so that the resulting motion for our positively-charged particle is counter-clockwise. The axial and planar equations of motion can then be obtained directly from the Lorentz Force law
Cyproheptadine is used to treat allergic reactions (specifically hay fever). There is evidence supporting its use for allergies, but second generation antihistamines such as ketotifen and loratadine have shown equal results with fewer side effects. It is also used as a preventive treatment against migraine. In a 2013 study the frequency of migraine was dramatically reduced in patients within 7 to 10 days after starting treatment. The average frequency of migraine attacks in these patients before administration was 8.7 times per month, this was decreased to 3.1 times per month at 3 months after the start of treatment. This use is on the label in the UK and some other countries. It is also used off-label in the treatment of cyclical vomiting syndrome in infants; the only evidence for this use comes from retrospective studies. Cyproheptadine is sometimes used off-label to improve akathisia in people on antipsychotic medications. It is used off-label to treat various dermatological conditions, including psychogenic itch, drug-induced hyperhidrosis (excessive sweating), and prevention of blister formation for some people with epidermolysis bullosa simplex. One of the effects of the drug is increased appetite and weight gain, which has led to its use (off-label in the USA) for this purpose in children who are wasting as well as people with cystic fibrosis.
5 October The New York Times summarizes those awarded Nobel Prizes in the Sciences for the year 2022: Physiology or Medicine (October 3): Svante Pääbo for discoveries involving genomes of extinct hominins Physics (October 4): Alain Aspect, John F. Clauser and Anton Zeilinger for work in quantum technology Chemistry (October 5): Carolyn R. Bertozzi, Morten Meldal and K. Barry Sharpless for studies on click chemistry and bioorthogonal chemistry. Scientists report the discovery of ongoing transfer of mitochondrial DNA into DNA in the cell nucleus. Previously, nuclear-mitochondrial segments (NUMT) were thought to have arisen only long ago. 66 thousand whole-genome sequences indicate this currently occurs as frequent as once in every ~4,000 human births. Researchers outline the large potentials and benefits of marine algae-based aquaculture for the development of a future healthy and sustainable food system. Scientists demonstrate the use of organoids for the study of brain development, identifying and investigating genetic switches that have a significant impact on it using single-cell transcriptome readouts.
Sources: en.wikipedia.org
De Vries acted as a close confidant to Nabil B., the crown witness in the Marengo trial whose own brother, alongside his lawyer, were assassinated by Taghi's organisation for exposing their inner workings. The person who is suspected of killing De Vries, is a relative of the person who is in charge of Taghi's hit squad, which gives the Dutch authorities more reason to believe that Taghi's organisation is responsible for the killing. However, it is still unclear who gave the order of the shooting, since Taghi himself was already in a high-security prison at the time of the shooting.
== Synthesis == Covalent Organic Frameworks (COFs) have also been used to form cage architectures and in one such example Schiff base cyclization was used to form the macromolecular cage molecule. In this synthesis 1,3,5-triformylbenzene and (R,R)-(1,2)-diphenylethylenediamine undergo cycloimination in dichloromethane with trifluoroacetic acid as a catalyst to form a COF cage molecule. Macrocyclizations have also been employed to form peptoid based macromolecular cages, the specific methodology utilizes a one pot synthesis to form steroid-aryl hybrid cages using two- and three-fold Ugi type macrocyclization reactions. Dynamic covalent chemistry enables the formation of thermodynamically stable cage structures through reversible bond formation. The formation of imine bonds through the reaction between aldehyde and amine groups represents a fundamental example of this chemistry. This reversible nature allows for continuous bond breaking and reforming during synthesis, enabling error correction and driving the system toward the most thermodynamically stable products. The dynamic nature of these reactions is particularly crucial in cage synthesis for several reasons. The ability to self-correct defects during formation ensures the production of highly ordered structures with minimal imperfections. The formation of thermodynamically favored products leads to stable and well-defined cage architectures that can maintain their structural integrity under various conditions.
{\displaystyle {\begin{aligned}{\frac {dS}{dt}}&=\Lambda -\mu S-{\frac {\beta IS}{N}}\\[8pt]{\frac {dI}{dt}}&={\frac {\beta IS}{N}}-\gamma I-\mu I\\[8pt]{\frac {dR}{dt}}&=\gamma I-\mu R\end{aligned}}}
24 June – Dunedin Airport receives its first international flight—a Jetstar flight from Gold Coast Airport—since the start of the COVID-19 pandemic in 2020. 25 June – Nelson Hospital switches from coal to landfill gas as part of a nationwide decarbonisation shift. 26 June: A state of emergency is declared in the Wairau-Awatere Ward of Marlborough due to heavy rain. 32 Māori land trusts (representing over 150,000 landowners, hapu (sub-groups) and iwi (tribes) file legal proceedings against the New Zealand Crown at the High Court urging the Government to stop the degradation of fresh water, honour the Treaty of Waitangi and Māori rights over water and geothermal resources. The New Zealand Government passed legislation designating the Independent Children's Monitor as an independent Crown entity, dissolving the Children and Young People's Commission and reinstating the Children's Commissioner. 27 June: A state of emergency is declared in Nelson and Tasman due to heavy rain and flooding . Residents of parts of Spring Creek are asked to evacuate in response to concerns that heavy overnight rain could cause the Wairau River to flood. New Zealand First list Member of Parliament Tanya Unkovich resigns to concentrate on work in the private sector. 28 June – A tornado in Waitara damages 11 homes. 29 June — The Government's sentencing reforms, which reduces sentencing discounts and encourages cumulative sentencing, comes into effect. 30 June – Oji Fibre Solutions ceases paper production operations at its Kinleith Mill in Tokoroa, affecting 230 jobs.
On the other hand, if the starting material is enough to develop more complete protocol, the amount of work to reach the separation goal depends on the available sample information and target molecule properties. Limits to development of purification protocols many times depends on the source of the substance to be purified, whether from natural sources (harvested tissues or organisms, for example), recombinant sources (such as using prokaryotic or eukaryotic vectors in their respective expression systems), or totally synthetic sources. No chromatographic techniques provide 100% yield of active material and overall yields depend on the number of steps in the purification protocol. By optimizing each step for the intended purpose and arranging them that minimizes inter step treatments, the number of steps will be minimized. A typical multistep purification protocol starts with a preliminary capture step which often utilizes ion exchange chromatography (IEC). The media (stationary phase) resin consists of beads, which range in size from being large (good for fast flow rates and little to no sample clarification at the expense of resolution) to small (for best possible resolution with all other factors being equal). Short and wide column geometries are amenable to high flow rates also at the expense of resolution, typically because of lateral diffusion of sample on the column. For techniques such as size exclusion chromatography to be useful, very long, thin columns and minimal sample volumes (maximum 5% of column volume) are required.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.